1st Quarter - Report

NOVARTIS for NOVARTIS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$3,280,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2018 $3,280,000 Replaced
1st Quarter - Amendment Jul 24, 2018 $3,060,000 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA Re-negotiation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN New —
SHAWN O'NEAIL —

Contacted: SENATE; Office of Management & Budget (OMB); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office

Foreign Relations FOR

Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform Treasury

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; Office of Management & Budget (OMB); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); State, Dept of (DOS); SENATE

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax Medical Device Tax Repeal & Suspension Section 385 Tax Regulation Tax Reform Orphan Drug Tax Tax Reform Border Adjustment Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Interest Deduction Debt Equity Regulations Tax Cuts & Jobs Act Implementation

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN New —
SHELLY MUI-LIPNIK New —
SHAWN O'NEAIL —

Contacted: State, Dept of (DOS); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN New —
SHELLY MUI-LIPNIK New —
SHAWN O'NEAIL —

Contacted: Food & Drug Administration (FDA); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); SENATE; Office of Management & Budget (OMB); State, Dept of (DOS); White House Office; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS)

Health Issues HCR

Cell & Gene Therapy, including reimbursement Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars PDUFA Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Biosimilar pass through payments Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs Part B Demo IPAB Generic Drug Labeling Outcomes-based Contracting Expanded Access PREA/BPCA BSUFA GDUFA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017 and related legislation Drug Compounding CMMI H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017 Tropical Disease Priority Review Voucher Clinical Trials H.R.2430 - FDA Reauthorization Act of 2017 H.R.849 - Protecting Seniors' Access to Medicare Act of 2017 Virtual Clinical Trials S2465 - Sickle Cell Disease Part D Donut Hole PAUSE Act DQSA Implementation Omnibus bill CR PAHPA Reauthorizing Biosimilar Pass Through Payments

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN New —
SHAWN O'NEAIL —

Contacted: U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); White House Office; Commerce, Dept of (DOC); Office of Management & Budget (OMB)

Bills named: H.R. 2430 (115th), S. 456 (115th), S. 204 (115th), H.R. 849 (115th), S. 469 (115th), H.R. 2641 (115th)

Medicare/Medicaid MMM

Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN New —
SHAWN O'NEAIL —

Contacted: Food & Drug Administration (FDA); State, Dept of (DOS); White House Office; U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2017 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars 2017 Agriculture Appropriations Bill Importation Drug Pricing Value of Meds

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN New —
SHAWN O'NEAIL —

Contacted: Office of Management & Budget (OMB); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); State, Dept of (DOS); White House Office; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.